Navigation Links
Monotherapy BYETTA(R) (exenatide) Injection Study Results Presented at ADA 2008 Showed Adults with Type 2 Diabetes Experienced Improved Glycemic Control and Weight Loss
Date:6/7/2008

and blood pressure levels improved. Systolic blood pressure decreased from baseline to endpoint by -3.7+/-1.2 mm Hg in the 5 mcg exenatide group (P=0.037; vs placebo) and also -3.7+/-1.2 mm Hg in the 10 mcg exenatide group (P=0.037; vs placebo), compared with -0.3+/-1.2 mm Hg for placebo (means +/- SEM). Diastolic blood pressure decreased from baseline to endpoint by -0.8+/-0.7 mm Hg in the 5 mcg exenatide group (P=0.619; vs placebo) and -2.3+/-0.7 mm Hg in the 10 mcg exenatide group (P=0.046; vs placebo), compared with -0.3+/-0.7 mm Hg for placebo (means +/- SEM).

There was an incidence of reported nausea in both the 5 mcg and 10 mcg arms of 3 and 13 percent, respectively, which is a lower incidence than what was observed in previous studies, where exenatide has been used in combination with other diabetes therapies. There were no instances of severe hypoglycemia. The overall incidence of hypoglycemia was similar to that seen in studies where exenatide was used in conjunction with metformin only.

Study Population

The 24-week, randomized study included 232 patients with type 2 diabetes who were not achieving adequate glucose control using diet and exercise without previous use of antidiabetes agents. Study participants were randomized to receive subcutaneous injections of placebo, 5 mcg exenatide, or 10 mcg exenatide twice daily without taking any oral antidiabetes agents. Patients randomized to 10 mcg exenatide received 5 mcg injections for the first four weeks, and increased to 10 mcg injections for the final 20 weeks.

About BYETTA(R) (exenatide) injection

BYETTA is the first and only FDA-approved incretin mimetic for the treatment of type 2 diabetes. BYETTA exhibits many of the same effects as the human incretin hormone glucagon like peptide-1 (GLP-1). GLP-1 improves blood sugar after food intake through multiple effects that work in concert on the stomach, liver, pancreas and brain. BYETTA is approved by the FDA for use by peop
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. TARGETED GENE DELIVERY IN VIVO: Rexin-G Monotherapy Reveals Significant Biological Activity Without Toxicity in Chemo-Resistant Metastatic Breast Cancer (ASCO 2008)
2. Roche and Pharmasset To Present the R7128 Monotherapy Resistance Profile
3. Multiple Clinical Trials of VELCADE(R) (Bortezomib) for Injection Based Therapies Demonstrate High Complete Remission Rates in Patients with Newly Diagnosed Multiple Myeloma
4. VELCADE(R) (Bortezomib) for Injection Based Treatment Delivers Impressive Complete Response and Survival in Patients With Newly Diagnosed Multiple Myeloma
5. New Eloxatin(R) (oxaliplatin injection) Prescribing Information in the U.S. Includes Six-Year Overall Survival Data
6. Ikaria Completes Dosing of Phase 1a Clinical Study for IK-1001 (Sodium Sulfide) for Injection
7. New Data Support High Complete Remission Rates With VELCADE(R) (Bortezomib) for Injection Based Therapies in Patients With Newly Diagnosed Multiple Myeloma
8. Patients Treated with Risperidone Long-Acting Injection had a Significantly Longer Time to Relapse Compared to Quetiapine in International Clinical Study
9. CorMatrix(R) Announces Intramyocardial Injection of Emulsified ECM Technology(TM) Demonstrates Enhanced Angiogenesis and Improved Cardiac Function in a Preclinical Model
10. Circulation Publishes Data Showing KYNAPID(TM) (Vernakalant Hydrochloride) Injection Rapidly Converted Short-Duration Atrial Fibrillation to Sinus Rhythm
11. Inclusion of Six-Year Overall Survival Data in the Eloxatin(R) (oxaliplatin injection) Prescribing Information Granted FDA Priority Review
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... 23, 2014  Lightlake Therapeutics Inc. ("Lightlake") (OTCQB: ... on its expertise in opioid antagonists, announced today ... application ("IND") with respect to its naloxone-based opioid ... that it has received an additional commitment from ... of the National Institutes of Health ("NIH"), to ...
(Date:7/23/2014)... , July 23, 2014  Silk Road Medical, ... transcarotid treatment of intra- and extra-cranial cerebrovascular disease, ... Wallace to the position of Chief Technology ... the company,s Research and Development efforts across its ... Prior to joining Silk Road Medical, ...
(Date:7/23/2014)... 2014  ACON Equity Partners III, L.P., a private ... announced it has completed the purchase of Injured Workers ... and Parthenon Capital Partners. IWP is a leading specialty ... Automobile Personal Injury Protection and Personal Injury pharmacy markets ... As part of this transaction, ACON partnered ...
Breaking Medicine Technology:Lightlake Therapeutics Inc. Files Investigational New Drug Application For Naloxone Nasal Spray For Reversing Opioid Overdose And Announces A Further Collaboration With The National Institute On Drug Abuse 2Lightlake Therapeutics Inc. Files Investigational New Drug Application For Naloxone Nasal Spray For Reversing Opioid Overdose And Announces A Further Collaboration With The National Institute On Drug Abuse 3Silk Road Medical Appoints Ground Breaking Innovator as Chief Technology Officer 2Silk Road Medical Appoints Ground Breaking Innovator as Chief Technology Officer 3ACON Investments Acquires Injured Workers Pharmacy 2ACON Investments Acquires Injured Workers Pharmacy 3
... Jan. 16, 2012 Boston Scientific Corporation (NYSE: ... its ORION trial, demonstrating excellent outcomes for the Company,s ... artery disease, a form of peripheral artery disease associated ... Results were presented today by Daniel Clair, M.D., FACS, ...
... SAN FRANCISCO, Jan. 16, 2012 Dicom Systems ( ... is pleased to announce their selection as the Vendor ... California-based full service physician-owned teleradiology group. ... you have the capacity to turn your current storage ...
Cached Medicine Technology:Boston Scientific Epic™ Stent Demonstrates Positive Clinical Outcomes in Orion Trial 2Boston Scientific Epic™ Stent Demonstrates Positive Clinical Outcomes in Orion Trial 3Boston Scientific Epic™ Stent Demonstrates Positive Clinical Outcomes in Orion Trial 4Boston Scientific Epic™ Stent Demonstrates Positive Clinical Outcomes in Orion Trial 5ONRAD, Inc. Chooses Dicom Systems' Vendor Neutral Archive 2
(Date:7/23/2014)... July 23, 2014 The age spots, wrinkles ... over the age of 30 are now explored in a ... the best eye creams for women over 30 are introduced ... http://cherrynews.com/best-nourishing-eye-serum . , The use of creams as an ... partly based on cost, according to the information in the ...
(Date:7/23/2014)... Edmond, Oklahoma (PRWEB) July 23, 2014 ... North America’s leading provider of in-home care for ... Healthy Longevity Webinar Series featuring experts in a ... upcoming webinar will feature licensed clinical social worker ... the most common causes of caregiver stress and ...
(Date:7/23/2014)... NY, July 24, 2014) If past experience is ... State are about to get a lot more recognition ... already on the books allowing NPs to provide primary ... patient care and better relationships with physicians and administrators, ... study from Columbia University School of Nursing, published in ...
(Date:7/23/2014)... Celebrating a decade of philanthropy in 2014, ... awarding of $1,070,000 in grants to 20 New Jersey ... the Foundation’s 1,000th grant. , “The Horizon Foundation for ... supporting community-based organizations that are working to improve public ... Garden State,” said Robert A. Marino, Horizon Blue Cross ...
(Date:7/23/2014)... growing body of research suggesting a safe and ... postmenopausal breast cancer, with fewer detrimental side effects ... therapies. The study will be published in final ... Biology and Endocrinology . , Breast cancer is ... the United States. Approximately 70% of breast cancers ...
Breaking Medicine News(10 mins):Health News:Best Eye Creams for Women Over 30 Detailed in Published Guide at News Website Online 2Health News:Oklahoma Home Care Assistance Hosting Caregiver Mindfulness Webinar Tomorrow 2Health News:Oklahoma Home Care Assistance Hosting Caregiver Mindfulness Webinar Tomorrow 3Health News:New York law offers nurses more recognition, responsibility 2Health News:The Horizon Foundation for New Jersey Awards More than $1 million in Grants to 20 Non-profit Organizations 2Health News:The Horizon Foundation for New Jersey Awards More than $1 million in Grants to 20 Non-profit Organizations 3Health News:The Horizon Foundation for New Jersey Awards More than $1 million in Grants to 20 Non-profit Organizations 4Health News:The Horizon Foundation for New Jersey Awards More than $1 million in Grants to 20 Non-profit Organizations 5Health News:Hormones after breast cancer: Not fuel for the fire after all? 2Health News:Hormones after breast cancer: Not fuel for the fire after all? 3Health News:Hormones after breast cancer: Not fuel for the fire after all? 4Health News:Hormones after breast cancer: Not fuel for the fire after all? 5
... MINNEAPOLIS, Oct. 17 Health Fitness Corp.,(OTC Bulletin Board: ... results for the third quarter ended September 30,2007, on ... Company also,announced that it will hold a conference call ... call will be Dr. Gregg Lehman, President and,Chief Executive ...
... Fla., Oct. 17 "As a physician,you hear all ... says Dr. Terry,D. Hashey, Medical Director of First Coast ... Corral Flu Campaign.,The most common that Dr. Hashey reports ... the flu shot. "That couldn,t be farther from the ...
... outcomes at Houston Northwest Medical ... nation,s best for several service lines, HOUSTON, ... Hospital Quality in America Study issued today, Houston,Northwest ... service,lines including overall gastrointestinal services, gastrointestinal,surgery, stroke, general ...
... that hospital-caused MRSA infections are about triple, previous estimates. The Centers ... and have failed to call on hospitals to take the ... ... infections., NEW YORK, Oct. 17 Today, data in an article,published ...
... WEST CHESTER, Ohio, Oct. 16 AtriCure, Inc.,(Nasdaq: ... leader in cardiac surgical,ablation products, today announced that ... which physicians have adopted to,treat atrial fibrillation (AF), ... Dr. James H. McClelland, an,electrophysiologist, and colleagues from ...
... breast cancer drugs called taxanes, which include Taxol (paclitaxel) ... part of chemotherapy following surgery for cancers that have ... research. , The review, which compared chemotherapy regimes ... studies including 21,191 women. , For patients, this study ...
Cached Medicine News:Health News:Health Fitness Corp. to Report Third Quarter 2007 Financial Results on November 5, 2007 2Health News:Flu Myths Abound in Flu Season 2Health News:Houston Northwest Medical Center's Patient Outcomes Superior 2Health News:Houston Northwest Medical Center's Patient Outcomes Superior 3Health News:The Journal of the American Medical Association (JAMA) Article Reveals Scope of MRSA Infections 2Health News:Published Results Using AtriCure Minimally Invasive Products 2Health News:Published Results Using AtriCure Minimally Invasive Products 3Health News:Taxol-type drugs give slight boost to survival rates in early breast cancer 2Health News:Taxol-type drugs give slight boost to survival rates in early breast cancer 3